Detail of "164656-23-9"

CAS Number:
164656-23-9
Name:
Dutasteride
Molecular Structure:
Formula:
C₂₇H₃₀F₆N₂O₂
Molecular Weight:
528.53
Synonyms:
4-Azaandrost-1-ene-17-carboxamide,N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-, (5a,17b)-;Avodart;1H-Indeno(5,4-f)quinoline-7-carboxamide,N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-;alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide;
Density:
1.303 g/cm³
Melting Point:
242-250 °C
Boiling Point:
620.3 °C at 760 mmHg
Flash Point:
329 °C
Solubility:
soluble in ethanol (44 mg/mL), methanol (64 mg/mL) and polyethylene glycol 400 (3 mg/mL), but it is insoluble in water
Appearance:
white crystalline solid

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

CAS No.164656-23-9 Dutasteride

DUTASTERIDE---We supply this product in very competitive price.

Supplier:Hangzhou UNIWISE International Co.,Ltd.[ China (Mainland)]

Verified-Platinum Supplier 2nd Year Platinum
Supplier 1525 Integral
1525

Contact:Mr. Victor Gale

Tel:+86-571-28819531

Fax:+86-571-28819532

Address:E-19F, Dongqiing Building, 52 Qingchun Rd, Hangzhou, China

Contact Suppliers

Total:58 Page 1 of 2 1 2 Next>>

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

The role of dutasteride in the treatment of benign prostatic obstruction and related conditions: All Rights Reserved. The role of dutasteride in the treatment of benign prostatic obstruction and related conditions. Davenport, K.; Abrams, P. (Bristol Urological Institute, Southmead Hospital, Bristol BS10 5NB, UK). Aging Health, 2(5), 745-752 (English) 2006 Future Medicine Ltd. CODEN: AHGECR. ISSN: 1745-509X. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Dutasteride is currently recommended for the treatment of symptomatic benign prostatic obstruction in men with bothersome lower urinary tract symptoms to improve symptoms, reduce the risk of acute urinary retention and reduce the need for surgery related to benign prostatic obstruction. Dutasteride is a dual inhibitor of the 5a-reductase isoenzymes types 1 and 2, which inhibit the conversion of testosterone to dihydrotestosterone. This redn. in intraprostatic dihydrotestosterone leads to a redn. in the size and vascularity of the prostate gland. Dutasteride is therefore highly effective in the treatment of lower urinary tract symptoms in the presence of benign prostatic enlargement. Dutasteride is assocd. with a 57% redn. in the risk of acute urinary retention requiring catheterization and a 47% redn. in the risk of surgical intervention as compared with placebo. In addn., dutasteride may also have a role in the chemoprevention of prostate cancer, prevention or treatment of hematuria related to benign prostatic enlargement and treatment of androgenic alopecia.Except for chemicals metioned above, 164656-23-9 is also used. .

Therapeutic strategies for managing BPH progression: All Rights Reserved. Therapeutic strategies for managing BPH progression. Fitzpatrick, John M.; Artibani, Walter (Department of Surgery, Mater Hospital, Dublin, Ire.). European Urology, Supplements, 5(20), 997-1003 (English) 2006 Elsevier B.V. CODEN: EUSUAU. ISSN: 1569-9056. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The aim of therapy for benign prostatic hyperplasia (BPH) is to improve quality of life by providing symptom relief and an increased max. flow rate (Qmax), as well as to reduce disease progression and the development of new morbidities. Watchful waiting can be recommended when the International Prostate Symptom Score is ￡7, i.e., mild symptoms that do not interfere with daily life activities. The a1-blockers are an established therapy for BPH and onset of action is rapid, generally within 2 wk of commencing treatment. Intermediate-term benefits can be seen in an improvement in Qmax of 10-15% and in symptom scores of 15-20%. The other main medical therapies for BPH are the 5a-reductase inhibitors (5ARIs), which not only reduce symptoms and improve Qmax, but also importantly reduce prostate vol. Dutasteride, a dual 5ARI, can provide benefits in symptom score and Qmax within 1 mo. The improvements in symptom score and Qmax continue up to 4 yr, with stabilization of prostate vol. In the long-term, unlike a1-blockers, 5ARIs reduce the risk of BPH progression. The risk of acute urinary retention for men taking dutasteride was reduced by 48% compared with placebo at 2 yr (p < 0.In this experiment, several chemicals are used like 164656-23-9 and 9081-34-9 001) and the risk of BPH-related surgery by 55% (p < 0.001). The combination of an a1-blocker and a 5ARI could be considered to provide added benefits over either therapy alone. .

Detail of "164656-23-9"

Dutasteride

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

CAS No.164656-23-9 Dutasteride

Reference